ArticleNature communications2025
Chiral recognition via symmetry-dependent luminescence in zero-dimensional hybrid copper halides.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Crown Ether-Ammonium Supramolecular Platform for Luminescent [CuACS physical chemistry Au · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chiral recognition through fluorescence changes enables the rapid and sensitive determination of enantiomers. However, the rational design and synthesis of fluorescent probes for efficient chiral recognition remain a challenge. Here we present a novel platform for chiral recognition based on zero-dimensional hybrid copper halides with unique symmetry-dependent properties. The use of mesomeric 1,2-diaminocyclohexane (DACH) ligands promotes the formation of centrosymmetric, non-luminescent Cu
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.